Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report)'s share price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $12.22 and traded as high as $13.95. Benitec Biopharma shares last traded at $13.78, with a volume of 89,004 shares changing hands.
Wall Street Analyst Weigh In
A number of research analysts recently commented on the company. Guggenheim downgraded Benitec Biopharma from a "buy" rating to a "neutral" rating in a report on Wednesday, June 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Benitec Biopharma in a research note on Friday, July 17th. Evercore assumed coverage on shares of Benitec Biopharma in a research report on Tuesday, May 12th. They set an "outperform" rating and a $25.00 price target for the company. Wedbush began coverage on shares of Benitec Biopharma in a report on Tuesday, July 28th. They issued an "outperform" rating and a $16.00 price target on the stock. Finally, Wall Street Zen raised shares of Benitec Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.80.
Check Out Our Latest Stock Analysis on Benitec Biopharma
Benitec Biopharma Stock Up 1.1%
The firm has a market capitalization of $473.34 million, a price-to-earnings ratio of -12.09 and a beta of 0.28. The stock has a 50 day moving average of $12.22 and a 200 day moving average of $11.86.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03. Analysts predict that Benitec Biopharma Limited will post -1.02 earnings per share for the current year.
Hedge Funds Weigh In On Benitec Biopharma
Several large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 904 shares during the last quarter. Truvestments Capital LLC lifted its position in shares of Benitec Biopharma by 156.5% in the 4th quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company's stock worth $52,000 after buying an additional 2,339 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Benitec Biopharma in the 3rd quarter valued at about $79,000. Bank of America Corp DE boosted its holdings in shares of Benitec Biopharma by 2,255.8% in the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company's stock valued at $80,000 after buying an additional 6,587 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of Benitec Biopharma during the 2nd quarter valued at about $80,000. 52.19% of the stock is currently owned by institutional investors.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Ltd NASDAQ: BNTC is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.
Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
